Arbutus Biopharma Corp Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Arbutus Biopharma Corp (ABUS) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$8.37 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-23
CAD
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2012-12-31 | 7.45M CAD 20-F · filed 2013-03-27 |
| 2011-12-31 | -2.63M CAD 20-F · filed 2013-03-27 |
| 2010-12-31 | -3.54M CAD 20-F · filed 2013-03-27 |
USD
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$8.37M 10-K · filed 2026-03-23 | |
| 2024-12-31 | -$18.89M 10-K · filed 2026-03-23 | |
| 2023-12-31 | -$19.67M 10-K · filed 2025-03-27 | |
| 2022-12-31 | -$17.55M 10-K · filed 2024-03-05 | |
| 2021-12-31 | -$23.86M 10-K · filed 2023-03-02 | |
| 2020-12-31 | -$17.21M 10-K · filed 2022-03-03 | |
| 2019-12-31 | -$44.92M 10-K · filed 2021-03-04 | |
| 2018-12-31 | -$16.56M 10-K · filed 2020-03-05 | -$19.29M 10-K · filed 2019-03-07 |
| 2017-12-31 | -$28.27M 10-K · filed 2019-03-07 | |
| 2016-12-31 | -$127.18M 10-K · filed 2018-03-16 | |
| 2015-12-31 | -$20.10M 10-K · filed 2018-03-16 | |
| 2014-12-31 | -$10.10M 10-K · filed 2017-03-22 | -$6.89K 10-K · filed 2015-03-13 |
| 2013-12-31 | -$3.49M 10-K · filed 2016-03-09 | -$2.38M 6-K · filed 2014-03-06 |
| 2012-12-31 | $7.49K 10-K · filed 2015-03-13 | $7.49M 6-K · filed 2014-03-06 |
| 2011-12-31 | -$2.59M 10-K · filed 2014-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |